After Seligman Investments distributed a "lengthy" short report on AxoGen that contributed to the stock declining by about 22% yesterday, JMP Securities analyst David Turkaly said he views the three most meaningful remarks as raising potential concerns over the company's previously stated addressable market size, portfolio of intellectual property and current market valuation. However, he believes AxoGen's sales growth, increased rep hiring, active account additions and guidance show that the market saturation suggested by the short report author is inconsistent with recent performance. The short also touched on the regulatory status of Avance, but Turkaly believes AxoGen has been taking adequate steps to successfully progress through its clinical pathway and "constructively communicate" with the FDA, the analyst added. He maintains an Outperform rating and $43 price target on AxoGen shares.